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Midkine antisense oligodeoxyribonucleotide inhibits renal
damage induced by ischemic reperfusion.
Background. Midkine, a heparin-binding growth factor, is
involved in the migration of inflammatory cells. The inflam-
matory cell migration to the tubulointerstitium of the kidney
after ischemia/reperfusion (I/R) injury is attenuated in midkine
gene–deficient mice, resulting in better preservation of the tubu-
lointerstitium compared with wild-type mice. In the present in-
vestigation, we planned to evaluate the usefulness of antisense
midkine for the therapy of ischemic renal failure.
Methods. Midkine antisense phosphorothioate oligodeoxyri-
bonucleotide (ODN) at a dose of 1 mg/kg in saline was intra-
venously administered to mice 1 day before or after I/R. The
kidneys were removed for examination 1, 2, 3, and 7 days after
I/R.
Results. It was rapidly incorporated into proximal tubular
epithelial cells, and inhibited midkine synthesis, leading to re-
duced migration of inflammatory cells to the injured epithelial
layer. Consequently, the midkine antisense ODN-treated ani-
mals exhibited less severe renal damage than untreated or mid-
kine sense ODN-treated animals 2 days after I/R as assessed by
morphologic criteria and blood urea nitrogen (BUN) and serum
creatinine levels. Midkine expression, BUN, and serum creati-
nine levels were not significantly different between injection of
midkine antisense ODN before and after ischemic injury.
Conclusion. These results indicate that intravenous injection
of midkine antisense ODN is a candidate for a novel therapeutic
strategy against acute tubulointerstitial injury induced by I/R
injury.
Migration of inflammatory leukocytes is a key event
in the cascade leading to pathologic tissue status such as
ischemic and autoimmune injury and atherosclerosis [1–
8]. Thus, means to interfere with the leukocyte migration
are intensely sought to prevent or treat various diseases.
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Ischemia/reperfusion (I/R) injury is one of the main
causes of acute renal failure in humans [9, 10]. Recently,
we found that midkine, a heparin-binding growth factor,
is involved in ischemic renal injury in a mouse model [4].
Midkine has 50% sequence identity with pleiotrophin,
but is not related to other growth factors or cytokines.
Midkine promotes the growth, survival, and migration of
various cells [4, 5, 11–17]. Midkine is fundamentally in-
volved in the migration of neutrophils and macrophages,
since it directly promotes their migration in vitro and
also induces chemokine expression [4, 5, 15]. Midkine
gene–deficient mice were found to show reduced tubu-
lointerstitial injury of the kidney [4] and neointima for-
mation of the carotid artery [5] upon ischemic insults,
due to the suppression of migration of inflammatory
leukocytes.
Based on these findings, we intended to interfere with
the development of ischemia-induced diseases by target-
ing midkine, and adopted antisense therapeutics, which
are synthetic oligonucleotides targeting molecular mech-
anisms of disease at the mRNA level [18, 19]. Currently,
numerous antisense therapeutics are being evaluated in
clinical trials for treating cancer, inflammation, and viral
diseases [18–24]. Most of the antisense therapeutics in de-
velopment are oligodeoxyribonucleotides (ODNs) with a
phosphorothioate internucleotide backbone. Phosphodi-
ester ODNs are rapidly degraded by nucleases and mod-
ification of the natural phosphodiester ODN is essential
for the survival of these agents when administered to hu-
mans or animals. The phosphorothioate backbone mod-
ification provides stability against nuclease degradation
and allows the administration of these compounds for lo-
cal and systemic therapies. Midkine antisense ODN to
suppress the synthesis of midkine has already been de-
signed, and it was shown to be effective in inhibiting the
growth of tumors pregrown in nude mice [25]. Therefore,
we planned to suppress the synthesis of midkine in the
renal tubules using phosphorothioate midkine antisense
ODN and to ameliorate the ischemic renal injury.
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METHODS
ODNs
Phosphorothioate-modified ODNs were synthesized
with an automated solid-phase nucleotide synthe-
sizer (Expedite 8900 Nucleic Acid Synthesis Sys-
tem) (Applied Biosystems, Foster City, CA, USA)
and subsequently purified using a Wakopak Handy
ODS column (Waters). Midkine antisense ODN, 5′-
AGGGCGAGAAGGAAGAAG-3′, corresponded to
bases 15 to 32 [25] in midkine cDNA [4]. Sense ODN,
5′-CTTCTTCCTTCTCGCCCT-3′, and scrambled ODN,
5′-GGGAAAAGAAACGGGAGG-3′, were used as a
control of the antisense DNA. We also used ODNs la-
beled with fluorescein isothiocyanate (FITC) at 5′ end,
which were synthesized and purified in a manner identi-
cal to the unlabeled one [26].
Cell culture and transfection of ODNs
CMT-93 cells (American Type Culture Collection,
Rockville, MD, USA) derived from mouse rectal carci-
noma were used to evaluate ODNs. Conditions of cell
culture and ODN transfection were as described previ-
ously [25].
Renal I/R injury
Male 129/SV mice at 8 to 10 weeks old were used
and fed normal rodent chow. The experiments described
below were carried out according to The Animal Ex-
perimentation Guide of Nagoya University School of
Medicine. A previously characterized mouse model of re-
nal I/R injury was used [4, 27]. The animals were placed
on a heating pad to keep a constant body temperature
(37◦C). Briefly, 7 days after removing the right kidney, the
mice were anesthetized and the left kidney was exposed.
The renal pedicles were bluntly dissected, and a nontrau-
matic vascular clamp was applied across the pedicles for
30 or 90 minutes. After the clamps were released, the
flanks were closed in two layers with 5-0 silk sutures. The
animals received 100 mL/kg warm saline instilled into the
peritoneal cavity during the procedure and were allowed
to recover with free access to food and water. One, 2, 3,
and 7 days after ischemia, the left kidneys were removed
for examination. In some experiments, 24 hours before
ischemic injury, the mice were treated with ODNs at a
dose of 1 mg/kg in saline by intravenous injection. Unless
otherwise specified, ODN was added 24 hours after the
ischemic injury, and experiments were performed using
12 mice.
Histology
The kidneys were fixed with 4% paraformaldehyde,
embedded in paraffin, and cut into 2 lm sections. They
were stained with periodic acid-Schiff (PAS) reagent. Us-
ing semiquantitative indices, the sections were analyzed
to evaluate acute tubulointerstitial damage in each re-
gion. Briefly, the extent of tubular cast formation, tubular
dilatation, and tubular degeneration (vacuolar change,
loss of brush border, detachment of tubular epithelial
cells, and condensation of tubular nuclei) in fields of both
cortex and medulla was scored according to the following
criteria by two observers in a blind manner: 0, normal; 1,
<30%; 2, 30% to 70%; and 3, > 70% of the pertinent
area [28].
Immunohistochemistry
Parts of the kidney tissues were snap-frozen in liquid
nitrogen and kept at −80◦C until use. Two micrometer
thick sections were cut with a cryostat and fixed in ace-
tone. The sections were then stained with rabbit anti-
mouse midkine and FITC-labeled goat antirabbit IgG
(Cappel, Durham, NC, USA). Rabbit antimouse mid-
kine was raised by injection of purified midkine pro-
duced in bacteria into rabbits, and was purified by affin-
ity chromatographies on protein A and midkine columns
[5]. The antibody was specific to midkine and did not
react to pleiotrophin/heparin binding growth associated
molecule (HB-GAM). After washing with phosphate-
buffered saline (PBS), all the sections were covered
with90% glycerol containing p-phenylenediamine and
were examined by an epifluorescence microscope (Olym-
pus Optical Co., Tokyo, Japan).
For the double immunofluorescence staining with
FITC-labeled midkine antisense ODN and proximal
tubule markers, 2 lm thick sections were cut with a cryo-
stat, fixed in acetone, and then incubated with goat an-
tirabbit angiotensin-converting enzyme (ACE) antibody
[29], followed by incubation with rhodamine-labeled rab-
bit antigoat IgG.
Cryosections were stained with a monoclonal rat an-
timouse monocyte-macrophage marker F4/80 (Serotec,
Ltd., Oxford, UK) or a monoclonal rat antimouse neu-
trophil marker 7/4 [30] (Serotec Ltd.) followed by detec-
tion with FITC-rabbit antirat IgG (Zymed Laboratories,
Inc, South San Francisco, CA, USA). Leukocytes posi-
tive for F4/80 or 7/4 were counted by examining 10 fields
of both cortex and medulla under a microscope at ×400
magnification in a blind manner.
Biochemical analyses
The blood was collected into a glass tube, left overnight,
and centrifuged at 1500 rpm for 10 minutes. Serum
creatinine and blood urea nitrogen (BUN) were mea-
sured using a Cre-Kainos Kit (Kainos Co. Ltd., Tokyo,
Japan) and Iatrochrom UN kit (Iatron Co. Ltd., Tokyo,
Japan), respectively. Proteins were separated by 15%
sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE), and midkine protein was detected by
Western blotting with antimouse midkine antibody using
an enhanced chemiluminescence (ECL) kit (Amersham,
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Buckinghamshire, UK). Northern blotting analysis was
performed as described previously [31, 32]. For quantita-
tive estimation, blots were scanned with Imaging Densit-
ometer Model GS-700 (Bio-Rad, Tokyo, Japan).
Statistical analysis
All values are given as means + SE. Statistical anal-
ysis was performed by one-factor analysis of variance
(ANOVA). When a significant difference was detected,
statistical analysis was further performed using the
Scheffe’s F test between two groups. A P value of < 0.05
was taken to indicate a significant difference.
RESULTS
Reperfusion model of 129/SV mice
We previously demonstrated a striking difference of re-
nal damages induced by reperfusion between wild-type
and midkine-deficient mice with 129/SV genetic back-
ground [4]. Therefore, in the present study, we used
129/SV mice to establish midkine roles in the reperfu-
sion injury model. Although most works on the reperfu-
sion renal injury model employed 30 minutes ischemia,
mouse strains used in these works are C57BL6J, BALB/c,
and NIH Swiss rather than 129/SV [27, 33]. We exam-
ined several conditions using 129/SV mice. 129/SV mice
were relatively resistant to reperfusion-induced renal in-
jury (Fig. 1). Thus, 30-minute ischemia showed little ef-
fect on renal function as estimated by BUN and serum
creatinine, while 90-minute ischemia resulted in severe
renal damage. However, the mortality of 90-minute is-
chemia was 0% among more than 100 mice examined
(data not shown). Therefore, we employed the condition
of 90-minute ischemia on 129/SV mice.
Inhibition of midkine synthesis in the kidney
with ischemic injury by midkine antisense ODN
Midkine antisense and scrambled ODNs were evalu-
ated for suppression of midkine expression using CMT-
93 cells, a mouse rectal carcinoma cell line. CMT-93 is
an adequate cell line for evaluation of the specificity
of ODNs because the transfection efficiency of ODN is
almost 100% in CMT-93, but is very low in primarily
cultured proximal tubule cells (data not shown). Mid-
kine antisense ODN strikingly suppressed midkine ex-
pression, while midkine scrambled ODN or saline control
did not (Fig. 2A and B). As previously reported, midkine
sense ODN showed no effect on midkine expression (data
not shown) [25]. Upon I/R injury, midkine expression
in the proximal tubular epithelial cells becomes signif-
icantly increased [4]. To inhibit the induced expression,
we planned to inject midkine antisense phosphorothioate
ODN intravenously. We first examined localization of
ODN absorbed in the kidney. When midkine antisense
ODN labeled with FITC was administered, it colocalized
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Fig. 1. Blood urea nitrogen (BUN) (A) and serum creatinine (sCr) (B)
levels of mice after ischemic/reperfusion (I/R) injury for 30 minutes or
90 minutes. BUN and serum creatinine were checked 0, 1, 2, 3, and 7 day
after ischemia. Ischemia for 90 minutes () and ischemia for 30 minutes
(). ∗P < 0.01 (N = 12).
with ACE, a marker of the proximal tubules [29], 8 hours
after administration (Fig. 2C to F).
Midkine antisense ODN significantly suppressed the
expression of midkine protein 2 days after I/R (i.e.,
24 hours after midkine antisense ODN treatment), com-
pared to midkine sense, scrambled ODN, or saline alone
(Fig. 3). Midkine protein expression returned to the nor-
mal level on day 7 when there was no significant differ-
ence between the midkine antisense ODN-treated group
and control group (Fig. 3).
Immunohistochemical staining for midkine revealed
that midkine expression in the proximal tubules was
strongly suppressed by treatment with midkine antisense
ODN (Fig. 4A) compared to treatment with sense, scram-
bled ODN, or saline treatment (Fig. 4B to D).
Suppression of renal damage by midkine antisense ODN
Histologic examination revealed that renal damage
2 days after I/R was less severe in the mice treated with
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Fig. 2. Western blot analysis for midkine expression in CMT-93 cells
and absorption of oligodeoxyribonucleotide (ODN) by the proximal
tubules. Midkine antisense ODN, scrambled ODN, or saline was trans-
fected into CMT-93 cells. Western blot analysis for midkine (A) and
b-actin (B) is shown. Results of three independent experiments were
reproducible, and a representative result is shown here. Lane 1, mid-
kine antisense ODN; lane 2, midkine scrambled ODN; lane 3, saline
control. Fluorescein isothiocyanate (FITC)-conjugated midkine anti-
sense ODN was injected intravenously to mice at 1 mg/kg. Eight hours
later, the kidney was processed for immunofluorescence analysis as de-
scribed in the Methods section. (C) FITC-labeled midkine antisense
ODN. (D) Anti-angiotensin-converting enzyme (ACE) (a marker for
the proximal tubules). (E) Merged image of (C and D). (F) Unstained
control. Bar, 50 lm.
midkine antisense ODN 24 hours after ischemia than in
those treated with midkine sense, scrambled ODN, or
saline alone (Fig. 5). Semiquantitative estimation of renal
damage, based on the degree of tubular cast formation,
tubular dilatation, and tubular degeneration, supported
the above observation (Fig. 6). Seven days after I/R, the
differences in the degree of ischemic injury were not sig-
nificant between the mice treated with midkine antisense
ODN, midkine sense ODN, midkine-scrambled ODN,
and saline alone (Fig. 6). Determination of BUN and
serum creatinine levels also led to the same conclusion
(Fig. 7). Data of Figure 7 also confirmed the overall pro-
file of the renal damage. BUN and serum creatinine levels
reach the maximum levels on day 2 in all negative con-
trols, while midkine antisense ODN significantly suppress
the levels on day 2 and 3.
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Fig. 3. Western blot analysis for midkine (MK) expression in the kid-
ney. Oligodeoxyribonucleotide (ODN) or saline was injected 1 day after
ischemic/reperfusion (I/R) injury. Two and 7 days after the injury, pro-
teins were extracted from the kidneys, and further used for Western
blot analysis for midkine (MK) protein. (A) Western blot analysis for
MK and b-actin. Lanes 1 and 5, midkine antisense ODN; lanes 2 and 6,
midkine sense ODN; lanes 3 and 7, midkine scrambled ODN; and lanes
4 and 8, saline control. C is no ischemia. (B) Intensity of bands relative
to that of saline control. Protein represents midkine normalized to b-
actin. Midkine antisense ODN (). Midkine sense ODN (). Midkine
scrambled ODN ( ). Saline control ( ). No ischemia ( ). ∗P < 0.01
(N = 12).
We found that on day 2 the number of migrated neu-
trophils and macrophages was significantly less in the
mice treated with midkine antisense ODN compared
with the sense, scrambled ODN, or saline-treated mice
(Fig. 8). The mRNA expression of macrophage inflam-
matory protein-2 (MIP-2), but not monocyte chemoat-
tractant protein-1 (MCP-1) or regulated on activation,
normal T-cell expressed and secreted (RANTES), was
reduced in the midkine antisense ODN-treated group
compared with other groups on day 2 (Fig. 9). Midkine
expression, BUN, and serum creatinine levels were not
significantly different between in injection of midkine an-
tisense ODN 24 hours before and after ischemic injury
(Fig. 10). The data suggest that midkine induction around
1 day after the initiation of the injury is crucial for pro-
motion of the injury.
DISCUSSION
In the previous study, we showed reduced susceptibility
of midkine-deficient mice to reperfusion-induced tubu-
lointerstitial injury, and clarified that midkine plays a key
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Fig. 4. Effects of midkine antisense oligodeoxyribonucleotide (ODN) in midkine expression on the proximal tubules. One day after is-
chemic/reperfusion (I/R) injury, either midkine antisense or sense ODN was injected intravenously at 1 mg/kg. The kidney was removed 2 days
after the injury, and then examined by immunofluorescence analysis using antimidkine antibody and fluorescein isothiocyanate (FITC)-conjugated
antirabbit IgG. (A) Midkine antisense ODN. (B) Midkine sense ODN. (C) Midkine scrambled ODN. (D) Saline control. (E) No ischemia. Bar,
50 lm.
Fig. 5. Tubulointerstitial damage in mice after ischemic/reperfusion (I/R) injury. The mice were injected with midkine antisense oligodeoxyribonu-
cleotide (ODN) (A), midkine sense ODN (B), midkine scrambled ODN (C), or saline (D) 1 day after the injury and, 2 days after, the kidneys were
removed and stained with periodic acid-Schiff (PAS). No ischemia control is also shown (E). Midkine antisense ODN-treated mice showed less
tubulointerstitial injury compared to the midkine sense or scrambled ODN- or saline-treated mice by all three criteria examined [i.e., tubular cast
formation (black arrow), tubular dilatation (arrowhead), and tubular degeneration (white arrow)]. Bar, 50 lm.
role in pathogenesis of this model [4]. Based on these re-
sults, we intended to cure the renal injury by knocking
down midkine in the present study. This study provided
two important findings, namely, the therapeutic poten-
tial of the midkine antisense reagent to counteract the
tubulointerstitial injury and the molecular hierarchy and
interaction of midkine and other cytokines in the injury.
Our result that the antisense ODN administered 24 hours
following injury ameliorated the renal damage is impor-
tant and clinically relevant, since most previous studies
required pretreatment, prior to the initiation of injury
[34, 35]. Importantly, administration of midkine antisense
ODN after the initiation of the injury exerted similar ef-
fects as the preventive administration of ODN before
the injury (Fig. 10). Tubulointerstitial injuries by renal is-
chemia are often observed in human kidneys after renal
transplantation or in kidneys with hypovolemic shock.
Our data clearly indicate that the effects of midkine an-
tisense ODN on mouse I/R injuries resulted mainly from
the interference of de novo synthesis of midkine in the dis-
eased tubules. Although midkine antisense ODN failed
to completely block I/R injuries, our results showing that
treatment begun after the onset of the disease had bene-
ficial effects support its therapeutic value. Further studies
are necessary to determine the therapeutic effects of mid-
kine antisense ODN in a chronic model of tubular injury.
As to the molecular hierarchy and interaction, we
should point to two issues before discussing the present
results. First, midkine has a direct chemotactic activity to
neutrophils and macrophages, as discussed in the pre-
vious report [4]. Second, the previous report demon-
strated that midkine deficiency causes decreased MIP-2
expression and diminished neutrophil infiltration dur-
ing early phase [4]. In addition, early phase infiltration
of macrophages is also suppressed in midkine-deficient
mice, but MCP-1 expression is not affected, and is closely
associated with late-phase macrophage infiltration [4].
The present study demonstrated that the midkine anti-
sense ODN suppressed not only midkine expression but
also MIP-2 expression (but not MCP-1 or RANTES ex-
pression). Therefore, it is likely that decreased MIP-2 ex-
pression observed in midkine-deficient mice is due to a
direct effect of loss of midkine rather than a chronic, in-
direct effect. Suppression of both midkine and MIP-2 ex-
pression led to diminished infiltration of neutrophils and
macrophages during the early phase, and consequently
ameliorates the renal damage. Supporting our data, anti-
MIP-2 antibody suppresses neutrophil infiltration and
ameliorates renal damage in a glomerulonephritis model,
in which MIP-2 is produced in the proximal renal tubules
[36]. Taken together, the present study strongly suggests
that MIP-2 is downstream of midkine, and both are es-
sential for early phase neutrophil infiltration in the reper-
fusion model.
In addition, the previous [4] and present studies col-
lectively elucidated that midkine is also involved in early
phase infiltration of macrophages, while MCP-1 expres-
sion is independent of midkine, and is closely associated
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Fig. 6. Semiquantitative analysis of tubulointerstitial damage. Experi-
ments were performed as in Figure 5. The degree of tubular cast forma-
tion (A), tubular dilatation (B), and tubular degeneration (C) was rated
as described in the Methods section. Two and 7 days after ischemia, mid-
kine antisense oligodeoxyribonucleotide (ODN)-treated mice showed
less tubulointerstitial injury compared to the midkine sense ODN- or
saline-treated mice. Data are shown as means (columns) and standard
errors (bar) (N = 12). Midkine antisense ODN (). Midkine sense ODN
(). Midkine scrambled ODN ( ). Saline control ( ). No ischemia ( ).
∗P < 0.01; ∗∗P < 0.001.
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Fig. 7. Blood urea nitrogen (BUN) (A) and serum creatinine (sCr) (B)
levels of mice 1, 2, 3, and 7 days after ischemic/reperfusion (I/R) injury.
The mice were administered with midkine antisense oligodeoxyribonu-
cleotide (ODN) (), midkine sense ODN (), midkine scrambled ODN
( ), or saline ( ) 1 day after the injury. No ischemia control is also shown
( ). ∗P < 0.01; ∗∗∗P < 0.05 (N = 12).
with late-phase macrophage infiltration. The gradual in-
duction of MCP-1, reaching the maximum level 7 days
after ischemia, in the present study is in contrast to previ-
ous studies, which report early responses, being the max-
imum 6 hours to 3 days after ischemia in a rat ischemia
model with 30-minute ischemia [37]. We speculate that
the discrepancy was caused by differences of species and
ischemic time. Considering that suppression of MCP-1 by
a dominant negative form of MCP-1 (an amino terminal
deletion mutant of MCP-1) diminishes macrophage in-
filtration and suppresses renal damage in a reperfusion
model [38], it is possible that incompleteness to ame-
liorate the I/R injury by the midkine antisense ODN is,
in part, due to the persistent expression of MCP-1 and
macrophage infiltration. In addition, RANTES is impor-
tant for infiltration of T cells and macrophages [39]. The
previous [39] and present study showed that the expres-
sion profile of RANTES is the same as that of MCP-1 in
reperfusion models. Therefore, attention should be also
paid to RANTES in the studies of pathogenesis of the
reperfusion-induced tubulointerstitial injury.
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Fig. 8. Neutrophil and macrophage infiltration 2 and 7 days after ischemic/reperfusion (I/R) injury. (A to E) Neutrophil 2 days after ischemia.
(F to J) Macrophage 2 days after ischemia. (A and F) Midkine antisense oligodeoxyribonucleotide (ODN). (B and G) Midkine sense ODN. (C
and H) Midkine scrambled ODN. (D and I) Midkine saline control. (E and J) No ischemia control. (K) Neutrophils. (L) Macrophages. The mice
were administered with midkine antisense ODN (), midkine sense ODN (), midkine scrambled ODN ( ) or saline ( ) 1 day after the injury. The
number of infiltrated neutrophils and macrophages were counted at indicated days as described in the Methods section. No ischemia control is also
shown ( ). ∗P < 0.01; ∗∗∗P < 0.05 (N = 12). Bar, 50 lm.
The results of the present investigation reinforce the
idea that midkine plays a central role in inflammatory
diseases. Midkine-targeted therapy should be generally
considered for the treatment of such diseases. Midkine
antisense ODN, which proved to be effective in inhibit-
ing renal damage, may be also useful for treatment of
other inflammatory diseases. However, it should be borne
in mind that while delivery of the reagent to the kid-
ney presented no problems, this may not be the case for
other organs. ODN, administered into the systemic circu-
lation, has been demonstrated to be selectively taken up
by the renal tubular epithelial cells in mice and rats [40–
42]. The intact ODNs are present in the cells even 4 days
after administration; reabsorption of ODNs filtered into
the Bowman’s space is considered to occur [40]. Proxi-
mal tubular epithelial cells are thought to take up ODN
efficiently, without any detectable degradation, through
the activity of ODN binding proteins on the brush bor-
der membrane [43]. Indeed, we demonstrated here that
midkine antisense ODN was efficiently taken up in the
proximal tubules. Since such a mechanism is not known
in other organs, the choice of delivery method should be
examined more closely for the treatment of other organs.
In addition to the mode of delivery, the side effects
are issues of primary concern in antisense therapeutics.
The adverse effects common to phosphorothioate ODN
and independent of the molecular target are lymphoid
proliferation, mononuclear cell infiltration to multiple
tissues, and degeneration and necrosis of the liver and re-
nal proximal tubules [44–47]. However, the side effects of
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Fig. 9. Macrophage inflammatory protein-2 (MIP-2), monocyte
chemoattractant protein-1 (MCP-1), or regulated on activation, nor-
mal T-cell expressed and secreted (RANTES) expression 2 and 7 days
after ischemic/reperfusion (I/R) injury. RNA was extracted from the
kidney and subjected to Northern blot analysis for MIP-2 and MCP-
1. The mice were administered with oligodeoxyribonucleotide (ODN)
or saline 1 day after the injury. (A) Northern blot analysis for MIP-2
mRNA, MCP-1 mRNA, and glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) mRNA. Lanes 1 and 4, midkine antisense ODN; lanes
2 and 5, midkine sense ODN; lanes 3 and 6, saline control. C is no
ischemia. Intensity of bands relative to that of no ischemia. mRNA rep-
resents MIP-2 (B), MCP-1 (C), and RANTES (D) mRNA normalized
to GAPDH mRNA. Midkine antisense ODN (). Midkine sense ODN
( ). Saline control ( ). No ischemia ( ). ∗P < 0.01 (N = 12).
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Fig. 10. Midkine (MK) expression (A), blood urea nitrogen (BUN)
(B) and serum creatinine (sCr) (C) levels of mice administrated with
oligodeoxyribonucleotide (ODN) or saline 1 day before or after is-
chemic injury. The kidney and blood was removed 2 days after the
initiation of the injury, and then examined by Western blot analysis
and biochemical analysis. C is control, no ischemia. Midkine antisense
ODN (). Midkine sense ODN (). Saline control ( ). No ischemia ( ).
∗P < 0.01; ∗∗∗P < 0.05 (N = 12).
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phosphorothioate ODNs are generally observed at doses
above 50 mg/kg. Indeed, in phase I clinical trials phospho-
rothioate ODNs are generally well tolerated at a dose of
10 mg/kg [21–23]. The dose of midkine antisense ODN
used in the present experiment was 1 mg/kg, and we ob-
served no apparent side effects caused by phosphoroth-
ioate ODNs.
Phosphorothioate ODN containing cytosine
phosphodiester-guanine (CpG) motifs is recognized
by macrophages, dendritic cells, and B cells as a danger
signal indicating bacterial infection [48, 49], and induces
murine B cells to proliferate and secrete immunoglob-
ulins in vitro and in vivo [50]. Since midkine antisense
ODN and control ODNs used in the present study
had no CpG immune stimulatory sequence, the above-
mentioned nonspecific stimulation of immune cells was
left out of consideration.
CONCLUSION
Midkine antisense ODN administered after I/R inhib-
ited midkine synthesis, leading to reduced migration of
inflammatory cells to the injured epithelial layer and re-
duced renal damage. These results indicate that intra-
venous injection of midkine antisense ODN is a candidate
for a novel therapeutic strategy against acute tubuloint-
erstitial injury induced by I/R injury.
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